BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
Overall BRM gets a fundamental rating of 6 out of 10. We evaluated BRM against 50 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. BRM also has an excellent dividend rating. With these ratings, BRM could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
In the past year BRM had a positive cash flow from operations.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BRM (5.86%) is comparable to the rest of the industry.
With an excellent Return On Equity value of 31.16%, BRM belongs to the best of the industry, outperforming 82.00% of the companies in the same industry.
The Return On Invested Capital of BRM (13.26%) is better than 72.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 15.13%.
The last Return On Invested Capital (13.26%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROIC | 13.26% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
Looking at the Profit Margin, with a value of 11.38%, BRM is in line with its industry, outperforming 56.00% of the companies in the same industry.
BRM has a better Operating Margin (27.11%) than 82.00% of its industry peers.
BRM's Operating Margin has declined in the last couple of years.
BRM has a better Gross Margin (74.69%) than 68.00% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BRM is creating some value.
Compared to 1 year ago, BRM has less shares outstanding
Compared to 5 years ago, BRM has less shares outstanding
Compared to 1 year ago, BRM has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.08 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of BRM (2.08) is comparable to the rest of the industry.
The Debt to FCF ratio of BRM is 3.80, which is a good value as it means it would take BRM, 3.80 years of fcf income to pay off all of its debts.
BRM has a better Debt to FCF ratio (3.80) than 62.00% of its industry peers.
A Debt/Equity ratio of 2.67 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a Debt to Equity ratio of 2.67. This is in the lower half of the industry: BRM underperforms 78.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Altman-Z | 2.08 |
ROIC/WACC1.51
WACC8.79%
2.3 Liquidity
BRM has a Current Ratio of 1.28. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a Current ratio of 1.28. This is in the lower half of the industry: BRM underperforms 64.00% of its industry peers.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 599.05%, which is quite impressive.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 4.62%.
BRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 38.96% on average per year.
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.38% yearly.
EPS Next Y498.29%
EPS Next 2Y132.62%
EPS Next 3Y75.28%
EPS Next 5Y38.96%
Revenue Next Year-4.37%
Revenue Next 2Y-5.38%
Revenue Next 3Y-3.84%
Revenue Next 5Y-4.38%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRM is valuated cheaply with a Price/Earnings ratio of 6.41.
Based on the Price/Earnings ratio, BRM is valued cheaper than 90.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 24.21. BRM is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 7.63, the valuation of BRM can be described as very cheap.
Based on the Price/Forward Earnings ratio, BRM is valued cheaply inside the industry as 88.00% of the companies are valued more expensively.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 20.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.41 | ||
| Fwd PE | 7.63 |
4.2 Price Multiples
BRM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRM is cheaper than 86.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 88.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.32 | ||
| EV/EBITDA | 6.34 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 75.28% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y132.62%
EPS Next 3Y75.28%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.00%, which is a nice return.
The stock price of BRM dropped by -23.87% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
BRM's Dividend Yield is rather good when compared to the industry average which is at 3.06. BRM pays more dividend than 92.00% of the companies in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
BRM pays out 90.59% of its income as dividend. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP90.59%
EPS Next 2Y132.62%
EPS Next 3Y75.28%
FRA:BRM (5/9/2025, 7:00:00 PM)
41.675
-0.21 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.77%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap84.81B
Analysts67.5
Price Target50.45 (21.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5% |
Yearly Dividend2.13
Dividend Growth(5Y)11.67%
DP90.59%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.3%
Min EPS beat(2)13.54%
Max EPS beat(2)17.07%
EPS beat(4)4
Avg EPS beat(4)19.02%
Min EPS beat(4)13.54%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)11.01%
EPS beat(12)11
Avg EPS beat(12)9.18%
EPS beat(16)15
Avg EPS beat(16)7.65%
Revenue beat(2)2
Avg Revenue beat(2)4.42%
Min Revenue beat(2)3.21%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.47%
Min Revenue beat(4)3.21%
Max Revenue beat(4)5.63%
Revenue beat(8)6
Avg Revenue beat(8)1.89%
Revenue beat(12)8
Avg Revenue beat(12)1.36%
Revenue beat(16)10
Avg Revenue beat(16)1.16%
PT rev (1m)-8.58%
PT rev (3m)-13.01%
EPS NQ rev (1m)-2.13%
EPS NQ rev (3m)-9.4%
EPS NY rev (1m)0.12%
EPS NY rev (3m)-2.93%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-4.01%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)-4.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.41 | ||
| Fwd PE | 7.63 | ||
| P/S | 2.01 | ||
| P/FCF | 7.32 | ||
| P/OCF | 6.7 | ||
| P/B | 5.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.34 |
EPS(TTM)6.5
EY15.6%
EPS(NY)5.46
Fwd EY13.1%
FCF(TTM)5.69
FCFY13.66%
OCF(TTM)6.22
OCFY14.94%
SpS20.72
BVpS7.56
TBVpS-11.67
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROCE | 18.89% | ||
| ROIC | 13.26% | ||
| ROICexc | 16.01% | ||
| ROICexgc | 72.41% | ||
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% | ||
| FCFM | 27.47% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.98%
ROICexgc(3y)70.34%
ROICexgc(5y)71.31%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Debt/EBITDA | 2.21 | ||
| Cap/Depr | 15.15% | ||
| Cap/Sales | 2.57% | ||
| Interest Coverage | 6.1 | ||
| Cash Conversion | 68.16% | ||
| Profit Quality | 241.48% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.08 |
F-Score7
WACC8.79%
ROIC/WACC1.51
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
EPS Next Y498.29%
EPS Next 2Y132.62%
EPS Next 3Y75.28%
EPS Next 5Y38.96%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
Revenue Next Year-4.37%
Revenue Next 2Y-5.38%
Revenue Next 3Y-3.84%
Revenue Next 5Y-4.38%
EBIT growth 1Y22.52%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year280.12%
EBIT Next 3Y50.48%
EBIT Next 5Y27.12%
FCF growth 1Y18.09%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y17.06%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%